Synergistic Treatment System for Malignant Lung Tumors
Legal Citation
Summary of the Inventive Concept
A comprehensive system integrating AI, IoT, blockchain, and new materials to enhance treatment efficacy and patient outcomes for malignant lung tumors
Background and Problem Solved
The original patent disclosed a selective inhibitor of exon 20 insertion mutant EGFR for treating malignant lung tumors. However, it had limitations in detecting and analyzing EGFR mutations, predicting treatment efficacy, and ensuring secure data sharing. The new inventive concept addresses these limitations by integrating distinct technologies to create a more powerful system
Detailed Description of the Inventive Concept
The system comprises a genetic testing module, an AI-based analysis module, and a database for storing EGFR mutation information. The AI module predicts treatment efficacy based on the detected mutation and stored information. Additionally, the system includes an IoT-enabled sensor network for identifying potential therapeutic agents and a blockchain-based secure data sharing platform for analyzing genomic data. The system also features a nanoparticle-based delivery system for targeted delivery of the selective inhibitor, composed of a new material with enhanced biocompatibility and stability
Novelty and Inventive Step
The new inventive concept combines the selective inhibitor of exon 20 insertion mutant EGFR with AI, IoT, blockchain, and new materials to create a synergistic system that enhances treatment efficacy and patient outcomes. The integration of these distinct technologies is novel and non-obvious compared to the original patent
Alternative Embodiments and Variations
Alternative embodiments may include using different AI algorithms, IoT sensor networks, or blockchain platforms. Variations may include integrating additional technologies, such as machine learning or genomics platforms, to further enhance the system's capabilities
Potential Commercial Applications and Market
The inventive concept has significant commercial potential in the pharmaceutical and healthcare industries, particularly in the development of personalized treatment plans for malignant lung tumors
CPC Classifications
| Section | Class | Group |
|---|---|---|
| A | A61 | A61K31/519 |
| A | A61 | A61P35/00 |
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Oncology, pharmaceutical biotechnology, with a focus on targeted cancer therapies and molecular diagnostics involving EGFR mutation analysis and personalized treatment strategies
Person of Ordinary Skill (PHOSITA) Profile
A skilled practitioner with advanced degrees in molecular biology, oncology, or biomedical engineering, possessing expertise in genetic testing, AI-driven medical analytics, and targeted therapeutic development
Obviousness Rationale
A PHOSITA would recognize that integrating advanced computational technologies with existing targeted cancer therapies represents a predictable and logical extension of precision medicine approaches. The combination of AI, IoT, and blockchain with the existing EGFR mutation treatment methodology demonstrates incremental innovation using known technological integration techniques. The PTD's approach of enhancing diagnostic and treatment methodologies through computational and material science approaches would be considered an obvious optimization of existing therapeutic strategies.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,513 |
|---|---|
| Title | Selective inhibitor of exon 20 insertion mutant EGFR |
| Assignee(s) | TAIHO PHARMACEUTICAL CO., LTD. |